不同依从性下血液结直肠癌筛查与粪便筛查的估计影响和价值

数据集获取（Figshare）

• 源站标题：Estimated impact and value of blood-based colorectal cancer screening at varied adherence compared with stool-based screening
• DOI：10.6084/m9.figshare.25721488.v2
• 发布日期：2024-05-13
• 文件数：2 个
• 文件总体积：917.09 KB
• 源站页面：https://tandf.figshare.com/articles/dataset/Estimated_impact_and_value_of_blood-based_colorectal_cancer_screening_at_varied_adherence_compared_with_stool-based_screening/25721488

命令行下载

curl -L -o "ijme_a_2349467_sm1820.docx" "https://ndownloader.figshare.com/files/46001962"
curl -L -o "ijme_a_2349467_sm1819.docx" "https://ndownloader.figshare.com/files/46001965"

文件清单

• ijme_a_2349467_sm1820.docx（205.98 KB）
• ijme_a_2349467_sm1819.docx（711.11 KB）

文件总体积 917.09 KB（源站 API 实测）。

数据加载示例（图像类）

from PIL import Image
import glob, os

files = (glob.glob(os.path.join(path, "**", "*.png"), recursive=True)
       + glob.glob(os.path.join(path, "**", "*.jpg"), recursive=True)
       + glob.glob(os.path.join(path, "**", "*.tif"), recursive=True))
print("图像文件数:", len(files))
img = Image.open(files[0]); print("尺寸/模式:", img.size, img.mode)

# torchvision Dataset 方式:
# from torchvision import datasets
# ds = datasets.ImageFolder(path)  # 要求 子目录=类别

目录组织与标注格式以源站说明和下载后实际文件为准。

数据说明

This analysis estimated the outcomes of triennial blood-based colorectal cancer (CRC) screening at various adherence, including perfect adherence, compared with triennial multi-target stool DNA (mt-sDNA) screening at the reported real-world adherence rate.
The validated CRC-AIM model simulated a US cohort of average-risk individuals receiving triennial screening with mt-sDNA or blood-based test from ages 45 to 75 years. Modeled specificity and sensitivity were based on reported data. Adherence was set at a real-world rate of 65.6% for mt-sDNA and at 65.6%, relative 10% incremental increases from 65.6%, or 100% for the blood-based test. Costs of mt-sDNA and the blood-based test were based on prices for clinically available tests ($508.87 and $895, respectively). Value-based pricing was estimated at a willingness-to-pay threshold of $100,000.
Both tests resulted in life-years gained (LYG), reduced CRC cases, and reduced deaths versus no screening. With adherence for mt-sDNA set at 65.6% and for blood-based test set at 100%, mt-sDNA resulted in 30% more LYG, 52% more averted CRC cases, and 32% more averted CRC deaths. At reported sensitivity and specificity rates, mt-sDNA at 65.6% adherence dominates (is more effective and less costly) the blood-based test at any adherence. There was no price at which triennial screening with the blood-based test at any adherence was cost-effective compared with mt-sDNA at 65.6% adherence.
Triennial screening with mt-sDNA resulted in better clinical outcomes at a lower cost compared with the modeled blood-based test even at perfect adherence, supporting application of blood-based tests only as a secondary screening option.
Blood-based colorectal cancer screening has lower diagnostic accuracy, lower clinical and health outcomes, and is more expensive than mt-sDNA, even with perfect blood-based screening participation. Although better than no screening at all, blood-based testing is unlikely to exceed performance of stool-based assessment unless a blood-based test is able to meaningfully detect precancerous growths.

许可

CC BY 4.0

引用

学术使用请引用 DOI 10.6084/m9.figshare.25721488.v2（source: https://tandf.figshare.com/articles/dataset/Estimated_impact_and_value_of_blood-based_colorectal_cancer_screening_at_varied_adherence_compared_with_stool-based_screening/25721488）。